Wire Stories
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with...